Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2020-09-02 Investor Presentation
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
109年09月法人說明會簡報 — 178620200902M001.pdf
Investor Presentation Classification · 95% confidence The document is titled '109年度法人說明會' which translates to '2020 Annual Corporate Presentation' or 'Investor Presentation' for the fiscal year 109 in the Taiwanese calendar (which corresponds to 2020). The content includes detailed company and product technology introductions, market data, international partnerships, product advantages, clinical data, and financial data such as consolidated income statements, balance sheets, and cash flow statements for the first half of 2020 and 2019. The document is lengthy (over 13,000 characters) and contains detailed operational and financial information, typical of an investor presentation. There is no indication that this is a full annual report (10-K) or an audit report. It is not a regulatory filing or announcement but a detailed presentation aimed at investors. Therefore, the best classification is Investor Presentation (IP).
2020-09-02 Chinese
109年09月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations (法人說明會) with details such as company code, name, date, time, location, and links to presentation materials. It does not contain financial statements or detailed financial analysis but rather information about upcoming or past investor presentations. This matches the description of an Investor Presentation (IP) filing type, which is a detailed presentation for investors focusing on financials, strategy, and market position. The document length is short and it is not an announcement of a report publication but the presentation itself or its schedule and materials. Therefore, the correct classification is Investor Presentation (IP).
2020-09-02 Chinese
公告本公司受邀參加中國信託綜合證劵舉辦之「中國信託證劵2020第三季投資論壇」
Investor Presentation Classification · 95% confidence The document is a short announcement (658 characters) about the company 1786 科妍 being invited to participate in a third quarter 2020 investment forum hosted by a securities firm. It includes details about the date, time, and location of a scheduled investor presentation and a brief agenda. There is no detailed financial data or comprehensive report content. The document serves as a notice of an upcoming investor presentation event rather than the presentation itself or a financial report. According to the classification rules, such announcements about investor presentations fall under the category 'Investor Presentation' (IP). Given the document's nature and content, the classification is IP with high confidence.
2020-09-01 Chinese
公告本公司國內第一次無擔保轉換公司債轉換價格調整事宜
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company regarding an adjustment in the conversion price of its domestic unsecured convertible bonds due to ex-dividend and ex-rights operations. It includes specific dates and details about the price adjustment but does not contain financial statements or detailed financial analysis. The document length is only 673 characters, indicating it is a brief regulatory announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it relates to bond conversion price adjustments, which affect the company's capital structure.
2020-08-18 Chinese
公告本公司與泰宗生物科技股份有限公司簽署海捷特加強 型關節腔注射劑、海捷特關節腔注射劑及海優樂膀胱灌注液等 三項產品之中國獨家總經銷合約。
Regulatory Filings Classification · 95% confidence The document is a public announcement from a listed company (科妍) about signing an exclusive distribution agreement with another company for certain medical products in China. It details the contract terms, product descriptions, and strategic business implications. There is no indication of financial statements, quarterly or annual report data, or regulatory certifications. The content is a business update related to a commercial contract and partnership, which fits best under general regulatory announcements. The document length is short (1233 characters), and it is not a report publication announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-08-10 Chinese
109年07月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, managers, and their related parties. It shows stock types, quantities held at different times, increases and decreases in holdings, and other related information. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a report publication, earnings release, or regulatory certification. The document is a detailed insider shareholding disclosure, which corresponds to the category of Director's Dealing (DIRS).
2020-08-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.